CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Set For Strong Growth Through 2036, Driven By Next-Generation Innovation And Expanding Patient Access

(MENAFN- GlobeNewsWire - Nasdaq) ALL care is shifting toward CAR-T, creating opportunities in earlier treatment, off-the-shelf platforms and CD7 targeting, while relapse, toxicity and manufacturing remain key unmet needs.

Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

CAR-T Cell Therapy in Acute Lymphoblastic Leukemia Market Poised for Continued Growth Through 2036

The CAR-T cell therapy in acute lymphoblastic leukemia (ALL) market is entering a period of sustained growth as innovative immunotherapies reshape treatment for patients with relapsed or refractory disease. The overall ALL market surpassed USD 1.80 billion across the seven major markets (7MM) in 2025, supported by the transition from conventional chemotherapy to targeted agents, monoclonal antibodies and advanced cellular therapies.

According to the "CAR-T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) - Market Insights, Epidemiology and Market Forecast - 2036" report, the CAR-T cell therapy market in ALL reached approximately USD 300 million in 2025 and is expected to expand at a compound annual growth rate of 6.8% from 2026 to 2036. The United States represented the largest regional market, generating approximately USD 220 million in 2025.

CAR-T Cell Therapy in ALL Market Highlights

• The CAR-T cell therapy in ALL market was valued at approximately USD 300 million across the 7MM in 2025.
• The market is forecast to grow at a 6.8% CAGR between 2026 and 2036.
• TECARTUS accounted for approximately 50% of 7MM CAR-T cell therapy revenue in 2025.
• AUCATZYL generated approximately USD 74 million in 2025, with 2026 sales anticipated to reach USD 120-135 million.
• Total incident ALL cases across the 7MM were estimated at approximately 12,000 in 2025.

Approved products including KYMRIAH (tisagenlecleucel), TECARTUS (brexucabtagene autoleucel) and AUCATZYL (obecabtagene autoleucel) have established CAR-T cell therapy as an important treatment option in B-cell ALL. CD19-directed therapies have produced complete remission rates of approximately 80-90% in pediatric and adult populations. However, relapse remains a major clinical concern, with nearly half of responding patients experiencing disease recurrence within one to two years.

CAR-T cell therapy can provide durable clinical benefit through a single administration while potentially reducing exposure to repeated salvage chemotherapy. Its introduction has materially changed treatment strategies for patients with primary refractory disease or early relapse after frontline therapy. Clinical studies are also evaluating CAR-T cell therapy in earlier treatment settings, where patients may have better outcomes before receiving multiple chemotherapy regimens.

Competitive Landscape and Emerging CAR-T Cell Therapies

The emerging CAR-T cell therapy pipeline includes lasmecabtagene timgedleucel, also known as Lasme-cel or UCART22; WU-CART-007, also known as soficabtagene geleucel or sofi-cel; CTD402; and S101. Leading companies active in the market include Novartis, Gilead Sciences and Kite Pharma, Autolus Therapeutics, Cellectis, Wugen and Imviva.

Lasme-cel is being developed as an allogeneic CAR-T cell therapy targeting CD22. Its alternative antigen target, one-time dosing and off-the-shelf availability may support its use in patients previously treated with CD19-directed therapies. Cellectis expects the first interim analysis from the pivotal Phase II UCART22 study in the fourth quarter of 2026, with a biologics license application anticipated in 2028.

WU-CART-007 is an investigational allogeneic CD7-directed CAR-T cell therapy for CD7-positive hematologic malignancies. In January 2026, Wugen received Breakthrough Therapy Designation from the US Food and Drug Administration for sofi-cel. The pivotal T-RRex study is evaluating the therapy in pediatric and adult patients with relapsed or refractory T-cell ALL and T-cell lymphoblastic lymphoma.

Development in T-cell ALL remains challenging because of its heterogeneous mutational landscape and limited number of targetable genetic lesions. Therapies directed at broadly expressed surface antigens such as CD7 may help overcome these constraints and expand the addressable CAR-T cell therapy population.

Approved CAR-T Cell Therapies in Acute Lymphoblastic Leukemia

AUCATZYL is approved in the United States, United Kingdom and European Union for eligible patients with relapsed or refractory B-cell ALL. Its modified CD19-binding design and tumor-burden-guided dosing approach are intended to maintain antitumor activity while supporting a manageable safety profile. The therapy is available through more than 70 treatment centers in the United States. NICE determined AUCATZYL to be cost-effective, supporting its UK launch in January 2026.

TECARTUS received FDA approval in October 2021 for adults with relapsed or refractory B-cell precursor ALL. The European Commission subsequently approved the therapy in September 2022 for adults aged 26 years and older. Its market leadership reflects strong uptake among eligible adult patients and its established position in the relapsed or refractory treatment setting.

KYMRIAH was the first CAR-T cell therapy approved in the United States for pediatric and young adult patients with relapsed or refractory B-cell ALL. The therapy demonstrated an 83% remission rate within three months in its pivotal clinical program. Its listed treatment cost is USD 475,000 in the United States and approximately USD 305,800 in Japan.

ALL Epidemiology and Treatment Trends

Approximately 12,000 incident ALL cases were recorded across the 7MM in 2025. In the United States, males represented about 56% of cases. Across the EU4 and the United Kingdom, B-cell lymphoblastic leukemia cases were nearly four times more common than T-cell lymphoblastic leukemia cases. In Japan, approximately 1,400 patients received treatment for first-line or relapsed disease in 2025, while around 150 received third-line or later therapy.

ALL treatment is stratified by age, disease lineage, relapse risk, Philadelphia chromosome status, molecular characteristics and overall health. Current treatment strategies may include multi-agent chemotherapy, tyrosine kinase inhibitors, immunotherapy, CAR-T cell therapy and allogeneic stem cell transplantation. Although allogeneic transplantation remains a potentially curative option after salvage therapy, its use is restricted by significant treatment-related morbidity and mortality.

Unmet Needs and Market Opportunities

• Complex CAR-T cell manufacturing, administration and treatment-center requirements
• Relapse following an initial response, including antigen-positive and antigen-negative recurrence
• CAR-T cell-associated toxicities, including cytokine release syndrome and neurologic events
• Limited CAR-T cell therapy options for T-cell ALL
• Geographic, reimbursement and healthcare infrastructure barriers
• Need for clinical evidence supporting earlier-line use

The report evaluates historical and forecast market performance from 2022 through 2036 across the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. It includes epidemiology-based forecasting, patient uptake, therapy-specific revenue, pricing trends, market access considerations, peak patient share, competitive benchmarking and pipeline analysis.

Primary research incorporates perspectives from key opinion leaders and subject-matter experts across institutions including the University of Pennsylvania, University Hospital of Wales, Macmillan Cancer Centre and University of Chicago Medicine. These insights support analysis of treatment adoption, accessibility, clinical practice, epidemiology, patient selection and emerging therapeutic opportunities.

The CAR-T cell therapy in acute lymphoblastic leukemia market is expected to benefit from broader treatment-center access, advancing allogeneic platforms, new antigen targets and potential expansion into earlier lines of therapy. Continued innovation from established market leaders and emerging biotechnology companies is likely to intensify competition while addressing persistent clinical and commercial gaps through 2036.

Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Executive Summary of CAR-T in ALL
4. Key Events
4.1. Upcoming Key Catalysts
4.2. Key Transactions And Collaborations
4.3. News Flow
5. Epidemiology and Market Forecast Methodology
6. CAR-T in ALL Market Overview at a Glance
6.1. Clinical Landscape Analysis (By Phase, Molecule Type, and RoA)
6.2. Market Share (%) Distribution of CAR-T Cell Therapy in ALL By Therapies in the 7MM, in 2025
6.3. Market Share (%) Distribution of CAR-T Cell Therapy in ALL By Therapies in the 7MM, in 2036
7. Disease Background and Overview
7.1. Introduction
7.1.1. Subtypes of ALL
7.1.2. Signs and Symptoms of ALL
7.1.3. Risk Factors and Causes of ALL
7.1.4. Pathogenesis of ALL
7.2. Diagnosis of ALL
7.2.1. Complete Blood Count (CBC) and Peripheral Blood Smear
7.2.2. Blood Chemistry Tests
7.2.3. Coagulation Tests
7.3. Bone Marrow Tests
7.3.1. Bone Marrow Aspiration and Biopsy
7.4. Lab Tests used to Diagnose and Classify ALL
7.4.1. Routine Exams with a Microscope
7.4.2. Cytochemistry
7.4.3. Flow Cytometry and Immunohistochemistry
7.5. Chromosome Tests
7.5.1. Fluorescent in situ Hybridization (FISH)
7.5.2. Polymerase Chain Reaction (PCR)
7.6. Imaging Tests
7.6.1. Computerized Tomography (CT) Scan
7.6.2. Magnetic Resonance Imaging (MRI) Scan
7.7. Stages of ALL
7.7.1. B-cell ALL Staging
7.7.2. T-cell ALL Staging
8. Current Treatment Practices: ALL
8.1. CAR-T Cell Therapy
8.1.1. CAR-T Structure
8.1.2. Antigen Selection
8.1.3. Manufacture and Delivery
8.1.4. Currently Approved CAR-T Cell Therapy in ALL
8.1.5. Advantages of CAR-T Cell Therapy
8.1.6. Limitations of CAR-T Cell Therapy
8.1.7. Future Directions
8.2. Other Treatment Options
8.3. Treatment Guidelines
9. Epidemiology and Patient Population of ALL
9.1. Key Findings
9.1.1. Assumptions and Rationale
9.1.2. Total Incident Cases of ALL in the 7MM
9.2. The United States
9.2.1. Total Incident Cases of ALL in the US
9.2.2. Gender-specific Incident Cases of ALL in the US
9.2.3. Age-specific Incident Cases of ALL in the US
9.2.4. Subtype-specific Incident Cases of ALL in the US
9.2.5. Genetic mutation-specific Incident Cases of ALL in the US
9.2.6. Total Treated Cases of ALL in the US
9.3. EU4 and the UK
9.3.1. Total Incident Cases of ALL in EU4 and the UK
9.3.2. Gender-specific Incident Cases of ALL in EU4 and the UK
9.3.3. Age-specific Incident Cases of ALL in EU4 and the UK
9.3.4. Subtype-specific Incident Cases of ALL in EU4 and the UK
9.3.5. Genetic mutation-specific Incident Cases of ALL in EU4 and the UK
9.3.6. Total Treated Cases of ALL in EU4 and the UK
9.4. Japan
9.4.1. Total Incident Cases of ALL in Japan
9.4.2. Gender-specific Incident Cases of ALL in Japan
9.4.3. Age-specific Incident Cases of ALL in Japan
9.4.4. Subtype-specific Incident Cases of ALL in Japan
9.4.5. Genetic mutation-specific Incident Cases of ALL in Japan
9.4.6. Total Treated Cases of ALL in Japan
10. Patient Journey
10.1. CAR-T Cell Patient Journey
11. Marketed Drugs
11.1. Competitive Landscape of Marketed CAR-T therapies
11.2. KYMRIAH (tisagenlecleucel): Novartis
11.3.1. Drug Description
11.3.2. Regulatory Milestones
11.3.3. Other Developmental Activities
11.3.4. Summary of Pivotal Trials
11.3.5. Clinical Development
11.3.5.1. Clinical Trial Information
11.3.6. Analyst Views
11.2.6. Product Profile
11.3. TECARTUS (brexucabtagene autoleucel): Gilead Sciences
11.3.1. Drug Description
11.3.2. Regulatory Milestones
11.3.3. Other Developmental Activities
11.3.4. Summary of Pivotal Trials
11.3.5. Clinical Development
11.3.5.1. Clinical Trial Information
11.3.6. Analyst Views
11.4. AUCATZYL (obecabtagene autoleucel): Autolus Therapeutics
11.3.1. Drug Description
11.3.2. Regulatory Milestones
11.3.3. Other Developmental Activities
11.3.4. Summary of Pivotal Trials
11.3.5. Clinical Development
11.3.5.1. Clinical Trial Information
11.3.6. Analyst Views
12. Emerging Drugs
12.1. Competitive Landscape of Emerging CAR-T Therapies
12.2. Lasmecabtagene timgedleucel (Lasme-cel/UCART22): Cellectis
12.2.1. Drug Description
12.2.2. Other Developmental Activity
12.2.3. Clinical Development
12.2.3.1. Clinical Trials Information
12.2.4. Analyst Views
12.3. WU-CART-007 (soficabtagene geleucel/sofi-cel): Wugen
12.3.1. Drug Description
12.3.2. Other Developmental Activity
12.3.3. Clinical Development
12.3.3.1. Clinical Trials Information
12.3.4. Analyst Views
13. CAR-T Cell Therapies in ALL: 7MM Analysis
13.1. Key Findings
13.2. Market Outlook
13.3. Conjoint Analysis
13.4. Key Market Forecast Assumptions
13.5. Total Market Size of CAR-T Cell Therapies in ALL in the 7MM
13.6. United States Market Size
13.6.1. Total Market Size of CAR-T Cell Therapies in ALL in the United States
13.6.2. Total Market Size by Therapies in the United States
13.7. EU4 and the UK Market Size
13.7.1. Total Market Size of CAR-T Cell Therapies in ALL in EU4 and the UK
13.7.2. Total Market Size by Therapies in EU4 and the UK
13.8. Japan Market Size
13.8.1. Total Market Size of CAR-T Cell Therapies in ALL in Japan
13.8.2. Total Market Size by Therapies in Japan
14. Unmet Needs of CAR-T Cell Therapies in ALL
15. SWOT Analysis of CAR-T Cell Therapies in ALL
16. KOL Views of CAR-T Cell Therapies in ALL
17. Market Access and Reimbursement of CAR-T Cell Therapies in ALL
17.1. United States
17.1.1. Centre for Medicare and Medicaid Services (CMS)
17.2. EU4 and the UK
17.2.1. Germany
17.2.2. France
17.2.3. Italy
17.2.4. Spain
17.2.5. United Kingdom
17.3. Japan
17.3.1. MHLW
17.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
17.5. Market Access and Reimbursement of CAR-T Cell Therapy in ALL Therapies
18. Appendix
18.1. Bibliography
18.2. Report Methodology
19. Analyst's Capabilities
20. Disclaimer
21. About the Publisher
List of Tables
Table 1: Summary of CAR-T Cell Therapy for Acute Lymphoblastic Leukemia Market and Epidemiology (2022-2036)
Table 2: WHO Classification of Acute Lymphoblastic Leukemia
Table 3: Summary of Recommendations for Adult Acute Lymphoblastic Leukemia
Table 4: Total Incident cases of Acute Lymphoblastic Leukemia in the 7MM (2022-2036)
Table 5: Total Incident cases of Acute Lymphoblastic Leukemia in the US (2022-2036)
Table 6: Gender-specific cases of Acute Lymphoblastic Leukemia in the US (2022-2036)
Table 7: Age-specific cases of Acute Lymphoblastic Leukemia in the US (2022-2036)
Table 8: Subtype-specific cases of Acute Lymphoblastic Leukemia in the US (2022-2036)
Table 9: Genetic mutation-specific cases of Acute Lymphoblastic Leukemia in the US (2022-2036)
Table 10: Total Treated cases of Acute Lymphoblastic Leukemia in the US (2022-2036)
Table 11: Total Incident cases of Acute Lymphoblastic Leukemia in EU4 and the UK (2022-2036)
Table 12: Gender-specific cases of Acute Lymphoblastic Leukemia in EU4 and the UK (2022-2036)
Table 13: Age-specific cases of Acute Lymphoblastic Leukemia in EU4 and the UK (2022-2036)
Table 14: Subtype-specific cases of Acute Lymphoblastic Leukemia in EU4 and the UK (2022-2036)
Table 15: Genetic mutation-specific cases of Acute Lymphoblastic Leukemia in EU4 and the UK (2022-2036)
Table 16: Total Treated cases of Acute Lymphoblastic Leukemia in EU4 and the UK (2022-2036)
Table 17: Total Incident cases of Acute Lymphoblastic Leukemia in Japan (2022-2036)
Table 18: Gender-specific cases of Acute Lymphoblastic Leukemia in Japan (2022-2036)
Table 19: Age-specific cases of Acute Lymphoblastic Leukemia in Japan (2022-2036)
Table 20: Subtype-specific cases of Acute Lymphoblastic Leukemia in Japan (2022-2036)
Table 21: Genetic mutation-specific cases of Acute Lymphoblastic Leukemia in Japan (2022-2036)
Table 22: Total Treated cases of Acute Lymphoblastic Leukemia in Japan (2022-2036)
Table 23: Comparison of Marketed CAR-T Cell Therapy for Acute Lymphoblastic Leukemia in the 7MM
Table 24: KYMRIAH, Clinical Trial Description, 2024
Table 25: TECARTUS, Clinical Trial Description, 2024
Table 26: Comparison of Emerging CAR-T Cell Therapy for Acute Lymphoblastic Leukemia
Table 27: Obe-cel, Clinical Trial Description, 2024
Table 28: UCART22, Clinical Trial Description, 2024
Table 29: WU-CART-007, Clinical Trial Description, 2024
Table 30: UCART19, Clinical Trial Description, 2024
Table 31: PBCAR0191, Clinical Trial Description, 2024
Table 32: AUTO1/22, Clinical Trial Description, 2024
Table 33: Key Market Forecast Assumption of CAR-T Cell Therapy for Acute Lymphoblastic Leukemia in the United States
Table 34: Key Market Forecast Assumption of CAR-T Cell Therapy for Acute Lymphoblastic Leukemia in EU4 and the UK
Table 35: Key Market Forecast Assumption of CAR-T Cell Therapy for Acute Lymphoblastic Leukemia in Japan
Table 36: Total Market Size of CAR-T Cell Therapies in Acute Lymphoblastic Leukemia in the 7MM, USD million (2022-2036)
Table 37: Total Market Size of CAR-T Cell Therapies in Acute Lymphoblastic Leukemia in the United States, USD million (2022-2036)
Table 38: Market Size by Therapies in the United States, USD million (2022-2036)
Table 39: Total Market Size of CAR-T Cell Therapies in Acute Lymphoblastic Leukemia in EU4 and the UK, USD million (2022-2036)
Table 40: Market Size by Therapies in EU4 and the UK, USD million (2022-2036)
Table 41: Total Market Size of CAR-T Cell Therapies in Acute Lymphoblastic Leukemia in Japan, USD million (2022-2036)
Table 42: Market Size by Therapies in Japan, USD million (2022-2036)
Table 43: Haute Autorite de Sante (HAS) assessment for KYMRIAH
List of Figures
Figure 1: Development of Acute Lymphoblastic Leukemia
Figure 2: Sign and Symptoms of Acute Lymphoblastic Leukemia
Figure 3: Risks Factors of Acute Lymphoblastic Leukemia
Figure 4: Philadelphia Chromosome Translocation (translocation between 9 and 22 chromosomes)
Figure 5: Cytogenetic and Molecular Genetic Abnormalities in Childhood Acute Lymphoblastic Leukemia
Figure 6: Genetic Pathogenesis of B Lymphoblastic Leukemia at Diagnosis and Relapse
Figure 7: Complete Blood Count
Figure 8: Bone Marrow Aspiration and Biopsy
Figure 9: Cytogenetic Analysis
Figure 10: Treatment Overview of Acute Lymphoblastic Leukemia
Figure 11: Manufacturing and Delivery of CAR?T Cells
Figure 12: Generations of CAR-T cells
Figure 13: Total Incident cases of Acute Lymphoblastic Leukemia in the 7MM (2022-2036)
Figure 14: Total Incident cases of Acute Lymphoblastic Leukemia in the US (2022-2036)
Figure 15: Gender-specific cases of Acute Lymphoblastic Leukemia in the US (2022-2036)
Figure 16: Age-specific cases of Acute Lymphoblastic Leukemia in the US (2022-2036)
Figure 17: Subtype-specific cases of Acute Lymphoblastic Leukemia in the US (2022-2036)
Figure 18: Genetic mutation-specific cases of Acute Lymphoblastic Leukemia in the US (2022-2036)
Figure 19: Total Treated cases of Acute Lymphoblastic Leukemia in the US (2022-2036)
Figure 20: Total Incident cases of Acute Lymphoblastic Leukemia in EU4 and the UK (2022-2036)
Figure 21: Gender-specific cases of Acute Lymphoblastic Leukemia in EU4 and the UK (2022-2036)
Figure 22: Age-specific cases of Acute Lymphoblastic Leukemia in EU4 and the UK (2022-2036)
Figure 23: Subtype-specific cases of Acute Lymphoblastic Leukemia in EU4 and the UK (2022-2036)
Figure 24: Genetic mutation-specific cases of Acute Lymphoblastic Leukemia in EU4 and the UK (2022-2036)
Figure 25: Total Treated cases of Acute Lymphoblastic Leukemia in EU4 and the UK (2022-2036)
Figure 26: Total Incident cases of Acute Lymphoblastic Leukemia in Japan (2022-2036)
Figure 27: Gender-specific cases of Acute Lymphoblastic Leukemia in Japan (2022-2036)
Figure 28: Age-specific cases of Acute Lymphoblastic Leukemia in Japan (2022-2036)
Figure 29: Subtype-specific cases of Acute Lymphoblastic Leukemia in Japan (2022-2036)
Figure 30: Genetic mutation-specific cases of Acute Lymphoblastic Leukemia in Japan (2022-2036)
Figure 31: Total Treated cases of Acute Lymphoblastic Leukemia in Japan (2022-2036)
Figure 32: Total Market Size of CAR-T Cell Therapies in Acute Lymphoblastic Leukemia in the 7MM, USD million (2022-2036)
Figure 33: Total Market Size of CAR-T Cell Therapies in Acute Lymphoblastic Leukemia in the United States, USD million (2022-2036)
Figure 34: Market Size by Therapies in the United States, USD million (2022-2036)
Figure 35: Total Market Size of CAR-T Cell Therapies in Acute Lymphoblastic Leukemia in EU4 and the UK, USD million (2022-2036)
Figure 36: Market Size by Therapies in EU4 and the UK, USD million (2022-2036)
Figure 37: Total Market Size of CAR-T Cell Therapies in Acute Lymphoblastic Leukemia in Japan, USD million (2022-2036)
Figure 38: Market Size by Therapies in Japan, USD million (2022-2036)
Figure 39: Health Technology Assessment
Figure 40: Reimbursement Process in Germany
Figure 41: Reimbursement Process in France
Figure 42: Reimbursement Process in Italy
Figure 43: Reimbursement Process in Spain
Figure 44: Reimbursement Process in the United Kingdom
Figure 45: Reimbursement Process in Japan
A selection of companies mentioned in this report includes, but is not limited to:

• Novartis
• Gilead Sciences
• Autolus
• Cellectis
• Wugen
• Imviva

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN16092026004107003653ID1111672477